We understand your need to know more about COVID-19. If you are on HUMIRA (adalimumab), please speak with your doctor regarding any questions you may have, including questions about the authorized COVID-19 vaccines.
To support you in your discussion with your doctor, further information about COVID-19 and vaccination may be found at the Centers for Disease Control site at coronavirus.gov.
Has COVID-19 made paying for your medicine a challenge? AbbVie may be able to help. 1.800.4HUMIRA
(includes HUMIRA Citrate-free)
Resources designed with you in mind
With HUMIRA Complete, answers to your questions about HUMIRA, treatment-related resources, and encouragement are ready for you when you need them. To learn more, call 1.800.4HUMIRA
For more information about what AbbVie is doing to address the global COVID-19 crisis, please visit https://www.abbvie.com/coronavirus.html.
*Terms and Conditions apply. This benefit covers HUMIRA® (adalimumab) alone or, for rheumatology patients, HUMIRA plus one of the following medications: methotrexate, leflunomide (Arava®), or hydroxychloroquine (Plaquenil®). Eligibility: Available to patients with commercial prescription insurance coverage for HUMIRA who meet eligibility criteria. Co-pay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law or by the patient’s health insurance provider. If at any time a patient begins receiving prescription drug coverage under any such federal, state, or government-funded healthcare program, patient will no longer be able to use the HUMIRA Complete Savings card and patient must call HUMIRA Complete at 1-800-4HUMIRA to stop participation. Patients residing in or receiving treatment in certain states may not be eligible. Patients may not seek reimbursement for value received from the HUMIRA Complete Program from any third-party payers. Offer subject to change or discontinuance without notice. Restrictions, including monthly maximums, may apply. Patients who are members of insurance plans that claim to reduce or eliminate their patients' out of pocket co-pay, co-insurance, or deductible obligations for certain prescription drugs based upon the availability of, or patient's enrollment in, manufacturer sponsored co-pay assistance for such drugs (often termed "maximizer" programs) will have an annual maximum program benefit of $6,000.00 per calendar year. This assistance offer is not health insurance.To learn about AbbVie’s privacy practices and your privacy choices, visit www.abbvie.com/privacy.html
Arava and Plaquenil are registered trademarks of their respective owners.